Posted by Michael Wonder on 24 Dec 2022
Valneva completes BLA submission to US FDA for its single shot chikungunya vaccine candidate
23 December 2022 - Valneva today announces that it has completed rolling submission of the biologics license application to the U.S. FDA for its single shot chikungunya vaccine candidate, VLA1553.
Valneva is seeking approval of its investigational chikungunya vaccine in persons aged 18 years and above.
